The DOI matches its Crossref record, with a small difference in title or year; 14 of the 14 references it cites were found in a registry or an index.
Pioglitazone and Bladder Cancer
Open accessAbstract
OBJECTIVE: The association between pioglitazone and bladder cancer has not been investigated in Asians. We aimed to investigate this association. RESEARCH DESIGN AND METHODS: A total of 1,000,000 individuals were randomly sampled from the National Health Insurance database, and incident cases of bladder cancer during the period from 1 January 2006 to 31 December 2009 were analyzed among 54,928 patients with type 2 diabetes and without previous bladder cancer. RESULTS: Among 165 incident case subjects, 10 (0.39%) were ever users and 155 (0.30%) were never users of pioglitazone (adjusted hazard ratio in full model 1.305 [95% CI 0.661–2.576]). All bladder cancer in ever users occurred within a duration of therapy <24 months, suggesting an early effect of pioglitazone on bladder cancer or late use of pioglitazone in high-risk patients. CONCLUSIONS: The association between pioglitazone and bladder cancer was not significant. However, confirmation of this finding is required because of the possible lack of statistical power owing to the small number of events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is also some suggestion of a possible link between pioglitazone and bladder cancer and therefore individuals with a history of bladder cancer or unexplained hematuria should probably not receive this drug.98,99”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
SIMPLE METHOD TO CALCULATE THE CONFIDENCE INTERVAL OF A STANDARDIZED MORTALITY RATIO (SMR)
Ulm, K. (1990) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115507 · Cited by 559
Estrategias para la elaboración de modelos estadísticos de regresión
Núñez, E., Steyerberg, E. W., & Núñez, J. E. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.01.019 · Cited by 287
Piccinni, C., Motola, D., Marchesini, G., & Poluzzi, E. (2011) · Diabetes Care · doi:10.2337/dc10-2412 · Cited by 239
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes
Dormandy, J., Bhattacharya, M., & van Troostenburg, A. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00002 · Cited by 227
Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan
Tseng, C. (2011) · Diabetologia · doi:10.1007/s00125-011-2171-z · Cited by 139
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–123 of 123
Sitagliptin and oral cancer risk in type 2 diabetes patients
Tseng, C. (2017) · Oncotarget · doi:10.18632/oncotarget.18239 · Cited by 9
Self-citationTseng, C. (2022) · BMC Cancer · doi:10.1186/s12885-022-09660-8 · Cited by 7
Self-citationReassessment of pioglitazone and bladder cancer based on FAERS database
Chen, H.-Y., Zhao, H., Yang, J., Zhang, Q., Yan, M.-M., & Qiu, X. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2390000 · Cited by 6
PPAR γ Agonists and the Future for Insulin Sensitizers
Henry, R. R., Erickson, D., & Ciaraldi, T. P. (2012) · The British Journal of Diabetes · doi:10.1177/1474651412459202 · Cited by 6
Is there any robust evidence showing that SGLT2 inhibitor predisposes to cancer?
Çöpür, S., Yıldız, A. B., Covic, A. C., & Kanbay, M. (2023) · European Journal of Clinical Investigation · doi:10.1111/eci.14131 · Cited by 6
Cancer biology in diabetes update: Focusing on antidiabetic drugs
Kawakita, E., & Kanasaki, K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14152 · Cited by 8
Juvenile oral angiofibroma in a female.
Reddy, B. K., Isaac, V., Nayak, M., & Prabhu, S. R. (1979) · PubMed · Cited by 6
Akther, S. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.16.002819 · Cited by 6
Xu, B., & Zhou, J. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03759-6 · Cited by 5
Jadhav, S., Shivane, V. K., Lila, A., Bandgar, T., & Shah, N. (2014) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.138765 · Cited by 4
Song, S. O., Kim, K. J., & Lee, B. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.6.462 · Cited by 4
Agrawal, P. K., Jain, A., Gautam, A., Nigam, A. K., Pursnani, N., & Farooqui, M. (2019) · Perspectives in Clinical Research · doi:10.4103/picr.picr_192_18 · Cited by 4
Hsieh, M., Hu, S.-Y., Liao, S.-H., Chang, C.-M., Hsieh, V. C., & How, C. (2021) · Emergency Medicine International · doi:10.1155/2021/4916777 · Cited by 3
Does Pioglitazone Increase the Risk of Bladder Cancer in Japanese Diabetic Patients?
Kaga, K. (2014) · Medical & Surgical Urology · doi:10.4172/2168-9857.1000147 · Cited by 3
Translational Endocrinology & Metabolism: Metabolic Surgery Update
DEL PRATO, S., & Lebovitz, H. E. (2012) · Translational endocrinology & metabolism · doi:10.1210/team.9781936704071 · Cited by 3
Pioglitazone: A prudent prescription
Kalra, S., Dhamija, P., & Sahay, R. K. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.111594 · Cited by 3
Singh, H., Joshi, D., Narula, S., Singla, M., Rohilla, R., & Singh, J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2053111 · Cited by 2
Health implications of prediabetes and the role of trace elements in insulin resistance
Amer, H. M., Aboelyazed, S., Elshafeey, F., & Elhalawany, S. H. (2025) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-025-00811-9 · Cited by 3
α-Glukosidase-Hemmer und Thiazolidindione (Glitazone)
Scherbaum, W. A. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0085-6 · Cited by 2
Tseng, C. (2023) · Cancers · doi:10.3390/cancers15174276 · Cited by 2
Self-citationPolemics of pioglitazone: an appraisal in 2015
Singh, A. K. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1054809 · Cited by 2
Kim, S.-Y. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.6.460 · Cited by 1
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.869
Metadata
- Authors
- Tseng, C.-H.
- Affiliations
- National Taiwan University (TW)
- Corresponding author
- Tseng, Chin-Hsiao
- ORCID
- Tseng, Chin-Hsiao
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-01-16
- Volume
- 35
- Issue
- 2
- Pages
- 278-280
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3263866
- OpenAlex
- W2157761919
- Cited by
- 123
- References
- 14
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 2 · 2019: 5 · 2018: 5 · 2017: 10 · 2016: 12 · 2015: 15 · 2014: 17 · 2013: 24 · 2012: 19
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Health Research Institutes
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- pioglitazone, bladder cancer, type 2 diabetes, drug safety, adverse drug reactions, Asian populations, thiazolidinediones, cancer risk
- MeSH terms
- Pioglitazone, Urinary Bladder Neoplasms, Female, Humans, Hypoglycemic Agents, Male, Asian People, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
